<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(Mark One)

           [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         For the quarterly period ended           Commission File Number
         ---------------------------------------------------------------
                 December 31, 2001                        0-11476

                                HEALTHWATCH, INC.
         ---------------------------------------------------------------
        (Exact Name of Small Business Issuer as Specified in Its Charter)

                  Minnesota                                   84-0916792
       -------------------------------                    -------------------
         (State or Other Jurisdiction of                   (I.R.S. Employer
          Incorporation or organization)                    Identification No.)


              1100 Johnson Ferry Road, Suite 670, Atlanta, GA 30342
              -----------------------------------------------------
                    (Address of Principal Executive Offices)

                                 (404) 256-0083
                ------------------------------------------------
                (Issuer's Telephone Number, Including Area Code)

                                       N/A

                   -------------------------------------------
              (Former Name, Former Address and Former Fiscal Year,
                         if Changed Since Last Report)

Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports) and (2) has been
subject to such filing requirements for the past 90 days.

                                 Yes X No ______

      Number of registrant's common shares outstanding at January 31, 2002
                                    4,483,782

            Transitional Small Business Disclosure Format (check one)
                                 Yes __ No X

<PAGE>

PART I.
FINANCIAL INFORMATION
ITEM I. FINANCIAL STATEMENTS


<TABLE>
<CAPTION>


                       HEALTHWATCH, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEET
                                DECEMBER 31, 2001
                                   (UNAUDITED)

                                                 ASSETS

<S>                                                                                 <C>


CURRENT ASSETS

     Cash                                                                            $     36,835
     Accounts receivable                                                                  213,498
     Note receivable, current portion                                                      55,000
     Inventory                                                                             19,527
     Other current assets                                                                 103,421
                                                                                     ------------
          TOTAL CURRENT ASSETS                                                            428,281
                                                                                     ------------

OTHER ASSETS

     Property and equipment, net of accumulated depreciation of $479,297                  134,975
     Note receivable, net of current portion                                              335,439
     Intangible assets, net of accumulated amortization of $1,440,709                   6,097,978
                                                                                     ------------
          TOTAL OTHER ASSETS                                                            6,568,392
                                                                                     ------------
               TOTAL ASSETS                                                          $  6,996,673
                                                                                     ============

                                  LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES

     Accounts payable and accrued expenses                                             $1,001,746
     Accrued payroll and payroll taxes                                                     96,791
     Debentures payable                                                                    25,000
     Deferred rent obligation                                                              33,246
     Note payable to a bank                                                               200,390
                                                                                     ------------
          TOTAL LIABILITIES (ALL CURRENT)                                               1,357,173
                                                                                     ------------


SHAREHOLDERS' EQUITY

     Cumulative preferred stock, 15,000,000 shares authorized, $.05 par
     value; $11,132,300 liquidation preference:

         Series P, 66,886 shares issued and outstanding                                     3,344
         Series C, 4,000 shares issued and outstanding                                        200
         Series D, 72,941 shares issued and outstanding                                     3,648
     Common stock, $.05 par value; 50,000,000 shares authorized:

         2,740,718 shares issued and outstanding                                          137,037
         1,743,064 shares to be issued                                                     87,153
     Additional paid-in capital                                                        41,776,147
     Unearned compensation                                                                (77,520)
     Accumulated deficit                                                              (36,290,509)
                                                                                     ------------
          TOTAL SHAREHOLDERS' EQUITY                                                    5,639,500
                                                                                     ------------
               TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY                            $  6,996,673
                                                                                     ============

   The accompanying notes are an integral part of these consolidated financial statements.

</TABLE>


                                       2

<PAGE>

                       HEALTHWATCH, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
              FOR THE THREE MONTHS ENDED DECEMBER 31, 2001 AND 2000


<TABLE>
<CAPTION>

<S>                                                                             <C>            <C>


                                                                                     2001           2000
                                                                                     ----           ----
SALES                                                                             $  259,230     $   79,356
COST OF SALES                                                                          9,382         15,312
                                                                                  ----------     ----------
     GROSS PROFIT                                                                    249,848         64,044
                                                                                  ----------     ----------

OPERATING EXPENSES
     Selling, general and administrative                                             433,161        958,340
     Depreciation and amortization                                                   387,043         70,202
     Research and development                                                         41,975         59,554
                                                                                 -----------    -----------
          Total operating expenses                                                   862,179      1,088,096
                                                                                 -----------    -----------

OPERATING LOSS                                                                      (612,331)    (1,024,052)
                                                                                 -----------    -----------

OTHER INCOME (EXPENSE)
     Loss from investment in Halis, Inc.                                                  --         (9,050)
     Realized loss on marketable securities                                               --         (4,010)
     Interest income                                                                      --         37,845
     Interest expense                                                                (18,413)        (6,401)
                                                                                 -----------    -----------
          Total other income (expense)                                               (18,413)       (18,384)
                                                                                 -----------    -----------

LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES                                 (630,744)    (1,005,668)
INCOME TAX BENEFIT                                                                   157,866             --
                                                                                 -----------    -----------
LOSS FROM CONTINUING OPERATIONS                                                     (472,878)    (1,005,668)
GAIN ON SALE OF SUBSIDIARY (NET OF INCOME TAX OF $157,866)                           236,800             --
                                                                                 -----------    -----------
NET LOSS                                                                         $  (236,078)   $(1,005,668)
                                                                                 ===========    ===========

BASIC AND DILUTED NET LOSS PER COMMON SHARE
     Loss from continuing operations                                             $  (472,878)   $(1,005,668)
     Less preferred stock dividends (undeclared)                                     222,646        223,521
     Less amortization of beneficial conversion option on Series D and
            Series P preferred stock                                                      --      1,495,845
                                                                                 -----------    -----------
     Loss from continuing operations available to common shareholders               (695,524)    (2,725,034)
     Gain on sale of subsidiary, net of income tax                                   236,800             --
                                                                                 -----------    -----------
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS                                        $  (458,724)   $(2,725,034)
                                                                                 ===========    ===========

NET LOSS PER COMMON SHARE, BASIC AND DILUTED
     Loss from continuing operations                                             $     (0.15)   $     (1.27)
     Gain on sale of subsidiary, net of income tax                                      0.05             --
                                                                                 -----------    -----------
     Net loss                                                                    $     (0.10)   $     (1.27)
                                                                                 ===========    ===========
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING                               4,475,032      2,142,751
                                                                                 ===========    ===========

 The accompanying notes are an integral part of these consolidated financial statements.

</TABLE>


                                       3

<PAGE>

                       HEALTHWATCH, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
               FOR THE SIX MONTHS ENDED DECEMBER 31, 2001 AND 2000

<TABLE>
<CAPTION>

<S>                                                                                <C>            <C>
                                                                                        2001           2000
                                                                                        ----           ----
SALES                                                                               $   589,782    $   183,622
COST OF SALES                                                                            26,885         37,888
                                                                                    -----------    -----------
     GROSS PROFIT                                                                       562,897        145,734
                                                                                    -----------    -----------

OPERATING EXPENSES
     Selling, general and administrative                                                654,957      1,873,679
     Depreciation and amortization                                                      775,199        127,911
     Research and development                                                            81,707         98,034
                                                                                    -----------    -----------
          Total operating expenses                                                    1,511,863      2,099,624
                                                                                    -----------    -----------

OPERATING LOSS                                                                         (948,966)    (1,953,890)
                                                                                    -----------    -----------

OTHER INCOME (EXPENSE)
     Loss from investment in Halis, Inc.                                                     --       (127,710)
     Realized loss on marketable securities                                                  --         (3,860)
     Interest income                                                                         68         95,949
     Interest expense                                                                   (20,793)       (10,015)
                                                                                    -----------    -----------
          Total other income (expense)                                                  (20,725)       (45,636)
                                                                                    -----------    -----------

LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES                                    (969,691)    (1,999,526)
INCOME TAX BENEFIT                                                                      177,893             --
                                                                                    -----------    -----------
LOSS FROM CONTINUING OPERATIONS                                                        (791,798)    (1,999,526)
INCOME FROM DISCONTINUED OPERATIONS (NET OF INCOME TAX OF $20,027)                       30,040
GAIN ON SALE OF SUBSIDIARY (NET OF INCOME TAX OF $157,866)                              236,800             --
                                                                                    -----------    -----------
NET LOSS                                                                            $  (524,958)   $(1,999,526)
                                                                                    ===========    ===========

BASIC AND DILUTED NET LOSS PER COMMON SHARE
     Loss from continuing operations                                                $  (791,798)   $(1,999,526)
     Less preferred stock dividends (undeclared)                                        445,292        447,042
     Less amortization of beneficial conversion option on Series D and
       Series P preferred stock                                                         763,095      2,991,690
                                                                                    -----------    -----------
     Loss from continuing operations available to common shareholders                (2,000,185)    (5,438,258)
     Income from discontinued operations, net of income tax                              30,040             --
     Gain on sale of subsidiary, net of income tax                                      236,800             --
                                                                                    -----------    -----------
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS                                           $(1,733,345)   $(5,438,258)
                                                                                    ===========    ===========

NET LOSS PER COMMON SHARE, BASIC AND DILUTED
     Loss from continuing operations                                                $     (0.45)   $     (2.54)
     Income from discontinued operations, net of income tax                                0.01             --
     Gain on sale of subsidiary, net of income tax                                         0.05             --
                                                                                    -----------    -----------
     Net loss                                                                       $     (0.39)   $     (2.54)
                                                                                    ===========    ===========
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING                                  4,465,078      2,142,751
                                                                                    ===========    ===========

 The accompanying notes are an integral part of these consolidated financial statements.

</TABLE>


                                       4

<PAGE>

                       HEALTHWATCH, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
               FOR THE SIX MONTHS ENDED DECEMBER 31, 2001 AND 2000

<TABLE>
<CAPTION>


<S>                                                                                         <C>             <C>
                                                                                                  2001           2000
                                                                                                  ----           ----
CASH FLOWS FROM OPERATING ACTIVITIES
     Net loss                                                                                $  (524,958)   $(1,999,526)
     Adjustments:
       Depreciation                                                                               28,867          7,112
       Amortization                                                                              746,332        120,799
       Loss from investment in Halis, Inc.                                                            --        127,710
       Loss on sale of marketable securities                                                          --          3,860
       Gain on sale of subsidiary                                                               (394,666)            --
       Stock options issued for services                                                          21,142             --
       Changes in assets and liabilities, net of effects of sale of subsidiary:
             Accounts receivable                                                                (178,639)       (13,888)
             Inventory                                                                             8,016         10,028
             Other current assets                                                                 79,950        (73,401)
             Other assets                                                                             --        (13,157)
             Accounts payable and accrued expenses                                              (124,613)       154,657
             Deferred revenue and customer deposits                                                   --         (1,989)
                                                                                             -----------    -----------
             Total adjustments                                                                   186,389        321,731
                                                                                             -----------    -----------
       Net cash used in operating activities                                                    (338,569)    (1,677,795)
                                                                                             -----------    -----------

CASH FLOWS FROM INVESTING ACTIVITIES
       Purchase of property and equipment                                                             --       (119,378)
       Proceeds from sale of marketable securities                                                    --      2,190,143
       Proceeds from sale of  subsidiary                                                         265,000             --
       Decrease in due from Halis, Inc.                                                               --       (108,553)
       Purchase of intangible assets, capitalized MERAD
         technology costs and other                                                                   --       (248,597)
                                                                                             -----------    -----------
         Net cash provided in investing activities                                                    --      1,713,615
                                                                                             -----------    -----------

CASH FLOWS FROM FINANCING ACTIVITIES
  Principal payments on note payable to a bank                                                   (24,200)            --
                                                                                             -----------    -----------
     Net cash used by financing activities                                                       (24,200)            --
                                                                                             -----------    -----------

NET INCREASE (DECREASE) IN CASH                                                                  (97,769)        35,820

CASH, BEGINNING OF PERIOD                                                                        134,604         16,264
                                                                                             -----------    -----------

CASH, END OF PERIOD                                                                          $    36,835    $    52,084
                                                                                             ===========    ===========


 The accompanying notes are an integral part of these consolidated financial statements.

</TABLE>
                                       5

<PAGE>

                       HEALTHWATCH, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                DECEMBER 31, 2001
                                   (UNAUDITED)

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF PRESENTATION

The accompanying unaudited financial statements have been prepared in accordance
with generally accepted accounting principles for interim financial information
and with the instructions to Form 10-QSB. Accordingly, they do not include all
of the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management, all
adjustments (consisting of normal recurring accruals) necessary for a fair
presentation of the Company's financial position as of December 31, 2001, and
its results of operations and cash flows for the three months and six months
then ended have been included. However, operating results for the interim
periods noted are not necessarily indicative of the results that may be expected
for the year ending June 30, 2002. This report should be read in conjunction
with the Company's financial statements and notes thereto contained in the
Company's annual report on Form 10-KSB for the year ended June 30, 2001.

ORGANIZATION AND NATURE OF BUSINESS

HealthWatch, Inc. ("HealthWatch") and subsidiaries (collectively the "Company")
was founded in 1983 and while continuing to be a supplier of parts and services
for noninvasive vascular diagnostic medical instruments to hospitals and medical
clinics throughout the United States, continues to evolve into primarily a
software information technology ("IT") company. The Company's virtual software
application utility (the "MERAD Systems") utilizes an advanced multi-media
object and relational database which creates knowledge objects that can be used
and reused in virtually unlimited numbers of combinations to provide efficient
applications that can be accessed in both an Internet and Intranet environment.
Headquartered in Atlanta, Georgia, HealthWatch has research and development,
marketing, sales and support capabilities in the healthcare IT sector.

The Company's objective is to become a leading provider of enterprise software
applications to process and manage transactions for physician offices,
hospitals, outpatient clinics, and other healthcare providers. As part of this
plan, the Company will offer and market enterprise software solutions, known as
the Heal Systems and the HES Systems. The HES Systems and the Heal Systems use
proprietary technology to distribute, in a compressed digital format, one system
that includes over 30 integrated applications for the management of a healthcare
enterprise's resources, patient data, clinical data, and finances. The HES
Systems and the Heal Systems were designed and built using the Company's
software application utility, MERAD Systems.

                                       6

<PAGE>

INTANGIBLE ASSETS

Intangible assets are being amortized over five years using the straight-line
method.

LONG-LIVED ASSETS

HealthWatch evaluates the carrying value of long-lived assets, including
intangibles, whenever events or changes in circumstances indicate that the
carrying value of the asset may be impaired. An impairment loss is recognized
when estimated undiscounted future cash flows expected to result from the use of
the asset, including disposition, is less than the carrying value of the asset.
If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying value exceeds the fair value of the
assets, as measured by discounted cash flows over the remaining life of the
assets.

SIGNIFICANT ESTIMATES

Management has estimated the undiscounted future cash flows that are expected to
result from the use of its technology. These estimates are based on current
letters of intent and anticipated future sales. Achieving these estimates
depends on the Company's success in implementing its sales plan and penetrating
the market with its available resources. Management's estimates of projected
cash flows are subject to risks and uncertainties of change affecting the
recoverability of the Company's intangible assets. Although management has made
its best estimate of these factors based on current conditions and information,
it is reasonably possible that changes could occur in the near term which could
adversely affect management's estimate of net cash flows expected to be
generated from its technology and the need for asset impairment write-downs. As
a result, the carrying amount of the Company's intangible assets of
approximately $6.1 million may be reduced materially in the near term.

REVENUE RECOGNITION

Revenue consists of software licensing fees, product and supply sales,
consulting services, and third party claims processing fees. The Company
recognizes revenue from product sales at the time ownership transfers to the
customer, principally at shipment. Revenues from licensing agreements are
recognized after shipment of the product and fulfillment of acceptance terms,
provided no significant obligations remain and collection of resulting
receivables are deemed probable. Service revenues are recognized when the
services are performed.

                                       7

<PAGE>

NET LOSS PER SHARE

Basic loss per share is calculated as net loss available to common shareholders
divided by the weighted average number of common shares outstanding for the
period. Diluted earnings per share reflects the potential dilution that could
occur from common shares issuable through stock options, stock warrants and
convertible debt and stock. As the Company's stock options, stock warrants and
convertible debt and stock are antidilutive for all periods presented, dilutive
loss per share is the same as basic loss per share.

INCOME TAXES

Deferred income tax assets and liabilities are recognized for the estimated tax
effects of temporary differences between the financial reporting and tax
reporting bases of assets and liabilities and for loss carryforwards based on
enacted tax laws and rates. A valuation allowance is used to eliminate deferred
income tax assets to the amount that is more likely than not to be utilized.

DEBENTURES PAYABLE

As of December 31, 2001, the Company had outstanding debentures with principal
totaling $25,000. The debentures accrue interest at an annual rate of 10%,
payable quarterly. The debentures matured on March 1, 1998, and are currently in
default as to the payment of principal and past due interest. The debentures,
including unpaid accrued interest, could be converted, at the option of the
holder, into shares of the Company's common stock. As of December 31, 2001,
$17,399 in accrued but unpaid interest was outstanding on the debentures. The
Company is attempting to reach an agreement with the remaining debenture holder
in an effort to resolve the amounts outstanding or otherwise bring the
debentures out of their default status.

NEW ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board (FASB) issued SFAS No.
141, "Business Combinations" and SFAS No. 142, "Goodwill and Other Intangible
Assets." SFAS No. 141 requires all business combinations initiated after June
30, 2001 to be accounted for using the purchase method. Under SFAS No. 142,
goodwill and intangible assets with indefinite lives are no longer amortized,
but are reviewed annually for impairment or more frequently if impairment
indicators arise. Separable intangible assets that have finite lives will
continue to be amortized over their useful lives. The amortization provisions of
SFAS No. 142 apply to goodwill and intangible assets acquired after June 30,
2001. With respect to goodwill and intangible assets acquired prior to July 1,
2001, the Company is required to adopt SFAS No. 142 effective July 1, 2002, but
may adopt the new statement beginning July 1, 2001. The Company is currently
evaluating the effects that adoption of the provisions of SFAS No. 142 will have
on its results of operations and financial position. As of June 30, 2001, the
Company has intangible assets, net of accumulated amortization, of approximately
$6.1 million, which will be subject to the transitional provisions of SFAS No.
142. Amortization expense was $746,332 and $120,799 for the six months ended
December 31, 2002 and 2001, respectively.

                                       8

<PAGE>

NOTE B - OPERATIONS

The accompanying financial statements have been prepared in conformity with
generally accepted accounting principles, which contemplate the continuation of
the Company as a going concern. However, the Company incurred net losses of
$524,958 for the six months ended December 31, 2001 and $3,937,367 for the year
ended June 30, 2001, and had a working capital deficiency of $928,892 at
December 31, 2001. The Company has sustained continuous losses from operations.
The Company has used, rather than provided, cash in its operating activities
during the six months ended December 31, 2001 and the year ended June 30, 2001
and has deferred payment of certain accounts payable and accrued expenses. Given
these results, additional capital and improved operations will be needed to
sustain the Company's operations.

Management's operating plan is to fund future operations by licensing the
Company's technology assets to organizations that have significant numbers of
users. Beginning July 2001, the Company entered into certain letters of intent
with these types of organizations. Through these agreements and future
agreements, the Company expects to generate sufficient cash flows to cover its
operating costs and to improve its financial position. In addition, the Company
significantly reduced its operating expenses beginning July 2001.

In view of the matters described, there is substantial doubt about the Company's
ability to continue as a going concern. The recoverability of the recorded
assets and satisfaction of the liabilities reflected in the accompanying balance
sheet is dependent upon continued operation of the Company, which is in turn
dependent upon the Company's ability to meet its financing requirements on a
continuing basis and to succeed in its future operations. There can be no
assurance that management will be successful in implementing its plans. The
financial statements do not include any adjustment that might result from the
outcome of this uncertainty.

NOTE C - GAIN ON SALE OF SUBSIDIARY

On October 9, 2001, the Company sold its claims processing subsidiary, ABAS, to
a company controlled by the President of ABAS. The sales agreement specifies a
maximum purchase price of $1,320,000. This purchase price consists of $265,000
paid at closing, $55,000 to be paid on or before June 1, 2002, and profit
sharing revenues of $1,000,000, of which $465,000 is guaranteed through a
five-year promissory note. The agreement also includes a marketing and
administrative services agreement to jointly pursue certain new technology-based
services and share in revenues. The sale resulted in a pre-tax gain of $394,666
($236,800 after estimated taxes). The non-interest bearing promissory note of
$520,000 has been discounted to $390,439 using a rate of 6.75% for five years.
The gain was computed using a sales price of $655,439 representing $265,000 paid
at closing, a discounted promissory note of $390,439, less net assets of ABAS of
$260,773.

                                       9

<PAGE>

The following is a summary of operations of ABAS included in the consolidated
financial statements of HealthWatch for the six months ended December 31, 2001
and 2000:

                                2001        2000
                            -----------    -----
      Sales                 $ 1,115,979    $  --
      Operating expenses      1,060,232       --
                            -----------    -----
         Operating income        55,747       --
                            -----------    -----
      Interest expense           (5,680)      --
                            -----------    -----
                            $    50,067    $  --
                            ===========    =====





                                       10

<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.

Forward Looking Statements

The following discussion of HealthWatch's financial condition and results of
operations contains forward looking statements within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act
of 1934, which are intended to be covered by the safe harbors created thereby.
These statements include the plans and objectives of HealthWatch for future
operations. The forward looking statements included herein are based on current
expectations that involve numerous risks and uncertainties. HealthWatch's plans
and objectives are based on certain assumptions including, but not limited to,
competitive conditions within the healthcare industry will not change materially
or adversely and that there will be no material adverse change in HealthWatch's
operations or business. Assumptions relating to the foregoing involve judgments
with respect to, among other things, future economic, competitive and market
conditions, as well as future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond HealthWatch's
control. Although HealthWatch believes that the assumptions underlying the
forward looking statements included herein are reasonable, the inclusion of such
information should not be regarded as a representation by HealthWatch, or any
other person, that the objectives and plans of HealthWatch will be achieved.

Financial Condition

Total assets at December 31, 2001 decreased $675,030 to $6,996,673 from
$7,671,703 at June 30, 2001. The decrease is primarily due to the amortization
of intangibles of $746,332, a reduction of $97,769 in cash used to reduce
current liabilities, offset by an increase in receivables of $569,078, of which
$390,439 is a note receivable due from the acquirer of ABAS. Current liabilities
at December 31, 2001 decreased $171,214 to $1,357,173 from $1,528,387 at June
30, 2001. The decrease is primarily due to the repayment of current liabilities.
Shareholders' equity at December 31, 2001 decreased $503,816 to $5,639,500 from
$6,143,316 at June 30, 2001. This decrease is primarily due to the net loss for
the six months ended December 31, 2001 of $524,958.

Results of Operations

Six months ended December 31, 2001 compared to six months ended December 31,
2000

Revenues increased $406,160, or 221.2% to $589,782 for the six months ended
December 31, 2001 from $183,622 during the same period in 2000. The increase
results from licensing revenues from the Company's Heal Systems, HES Systems and
MERAD Systems.

Cost of products sold decreased $11,003 or 29.0% to $26,885 for the six months
ended December 31, 2001 from $37,888 during the same period in 2000. The
decrease is primarily due

                                       11

<PAGE>

to the continued shift from product sales to service and support at Healthwatch
Technologies.

Gross margins increased to $562,897, 95.4%, for the six months ended December
31, 2001 from $145,734, 79.4%, during the same period in 2000. Higher gross
margins were achieved from the revenue generated from the HES System and the
continued shift from product sales to service and support at Healthwatch
Technologies.

Selling, general and administrative expenses decreased $1,218,720 or 65.0% to
$654,959 for the six months ended December 31, 2001 from $1,873,679 during the
same period in 2000. This decrease was primarily due to a decrease in
compensation expense, the discontinuance of payments to Halis under the business
collaboration agreement subsequent to the merger, and general reductions in
operating expenses.

Research and development expenses decreased $16,327 or 16.7% to $81,707 for the
six months ended December 31, 2001 as compared to $98,034 during the same period
in 2000. The decrease was primarily due to additional development work performed
during the six months ended December 31, 2000.

Depreciation and amortization increased $647,286 to $775,197 for the six months
ended December 31, 2001 from $127,911 during the same period in 2000. The
increase is primarily the result of amortization expense of $600,324 related to
intangible assets acquired in the Halis merger which was effective May 31, 2001.

Equity loss from investment in Halis decreased from $127,710 to zero due to the
consummation of the Halis merger.

Interest income decreased $95,881 to $68 for the six months ended December 31,
2001 as compared to $95,949 during the same period in 2000. The decrease is due
to the sale of marketable securities used for working capital purposes.

Interest expense increased $10,778 to $20,793 for the six months ended December
31, 2001 as compared to $10,015 during the same period in 2000. The increase is
due to interest on notes payable to a bank acquired in the Halis merger.

Three months ended September 30, 2001 compared to three months ended September
30, 2000

Revenues increased $179,874, or 226.7% to $259,230 in the second quarter ended
December 31, 2001 from $79,356 during the same period in 2000. The increase
results from licensing revenues from the Company's Heal Systems, HES Systems and
MERAD Systems.

Cost of products sold decreased $5,930 or 38.7% to $9,382 in the second quarter
ended December 31, 2001 from $15,312 during the same period in 2000. The
decrease is primarily due to the continued shift from product sales to service
and support at Healthwatch Technologies.

Gross margins increased to $249,848, 96.4%, in the second quarter ended December
31, 2001

                                       12

<PAGE>

from $64,044, 80.7%, during the same period in 2000. Higher gross margins were
achieved from the revenue generated from the HES System and the continued shift
from product sales to service and support at Healthwatch Technologies.

Selling, general and administrative expenses decreased $525,179 or 54.8% to
$433,161 in the second quarter ended December 31, 2001 from $958,340 during the
same period in 2000. This decrease was primarily due to a decrease in
compensation expense, the discontinuance of payments to Halis under the business
collaboration agreement subsequent to the merger, and general reductions in
operating expenses.

Research and development expenses decreased $17,579 or 29.5% to $41,975 in the
second quarter ended December 31, 2001 as compared to $59,554 during the same
period in 2000. The decrease was primarily due to additional development work
performed during the second quarter ended December 31, 2000.

Depreciation and amortization increased $316,841 to $387,043 in the second
quarter ended December 31, 2001 from $70,202 during the same period in 2000. The
increase is primarily the result of amortization expense of $300,162 related to
intangible assets acquired in the Halis merger which was effective May 31, 2001.

Equity loss from investment in Halis decreased from $9,050 to zero due to the
consummation of the Halis merger.

Interest income decreased $37,845 in the second quarter ended December 31, 2001
as compared to $37,845 during the same period in 2000. The decrease is due to
the sale of Marketable Securities used for working capital purposes.

Interest expense increased $12,012 to $18,413 in the second quarter ended
December 31, 2001 as compared to $6,401 during the same period in 2000. The
increase is due to interest on notes payable to a bank acquired in the Halis
merger.

Liquidity and Capital Resources

At December 31, 2001, HealthWatch had a cash balance of $36,835. During the six
months ended December 31, 2001, operating activities consumed $338,569 of cash
as compared to $1,677,795 for the same period in 2000. The decrease in cash used
in operations is primarily the result of lower expenses, including the
discontinuance of payments to Halis under the business collaboration agreement
subsequent to the merger, and an increase in license revenues of the Company's
HES System.

Investing activities provided $265,000 cash during the six months ended December
31, 2001 representing proceeds from the sale of ABAS. Cash provided for the same
period in 2000 of $1,713,615 primarily represents proceeds from the sale of
marketable securities of $2,190,143 offset by capitalized MERAD technology costs
of $248,597.

Financing activities used $24,200 cash during the six months ended December 31,
2001. In the

                                       13

<PAGE>

first quarter 2001, the Company made principal payments on the note payable to a
bank acquired in the Halis merger, which was effective May 31, 2001.

The Company has begun to implement its business plan. Currently, HealthWatch
does not have any material commitments outstanding for capital expenditures and
does not anticipate making any material capital expenditures in the short term.
HealthWatch is not currently generating positive cash flow from its operations,
and does not currently have liquid assets necessary to sustain operations over
the next twelve months. Management believes that it will be able to provide the
necessary operating capital from sales of its products and services. However, if
HealthWatch is unable to generate sufficient cash flow from its business it will
be necessary to seek additional equity or debt financing. There can be no
assurance that the Company will be successful in obtaining additional financing
under acceptable terms, if at all.

                                       14

<PAGE>

PART II.
OTHER INFORMATION

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

During the quarter ended December 31, 2001, the Company issued 26,834 shares of
common stock as a result of the conversion of 939 shares of Series D preferred
stock.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

On March 1, 1998, $580,000 principal amount of the Company's 10% secured
convertible debentures ("Debentures") were due and payable. The Company was
unable to pay the Debentures in accordance with their terms and the Company
obtained no further extension of the maturity date from the holders. During
fiscal 1999, $100,000 in principal of the Debentures was paid to the holders
thereof. In January and February 2000, the Debenture holders converted $455,000
of their Debentures and related accrued interest of $139,357 into 316,990 shares
of common stock of the Company. As of December 31, 2001, a principal balance of
$25,000 remains outstanding.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to a vote of the Company's shareholders during
the second quarter ended December 31, 2001.

                                       15

<PAGE>

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a)  EXHIBITS. The following exhibits are filed with or incorporated by
     reference into this report:

      2.1  Agreement and Plan of Merger by and among Halis, Inc., HealthWatch
           Merger Sub, Inc. and HealthWatch, Inc. dated as of June 29, 2000 (1).
      2.2  Amendment to the Agreement and Plan of Merger dated as of September
           29, 2000 (1).
      2.3  Letter of Intent between HealthWatch, Inc. and Halis, Inc. dated
           March 8, 2000 (1).
      2.4  Amendment to the Financing Option between HealthWatch, Inc. and
           Halis, Inc. dated July 28, 2000 (1).
      2.5  Second Amendment to the Agreement and Plan of Merger, dated as of
           January 31, 2001 (1).
      3.1  Articles of Incorporation of HealthWatch, Inc., dated June 10, 1983
           (1).
      3.2  Certificate of Amendment of Articles of Incorporation of HealthWatch,
           Inc., dated October 20, 1987(1)
      3.3  Articles of Amendment of Articles of Incorporation of HealthWatch,
           Inc., dated December 5, 1989 (1).
      3.4  Articles of Amendment of Articles of Incorporation of HealthWatch,
           Inc., dated December 8, 1999 (1).
      3.5  Bylaws of HealthWatch, Inc. (1).
     3.13  Certification of Designation, Preferences, Rights and Limitations of
           the 6% Series A Convertible Preferred Stock of HealthWatch, Inc.
           dated June 9, 1998 (1).
     3.14  Amended and Restated Certification of Designation, Preferences,
           Rights and Limitations of the Series P Preferred Stock of
           HealthWatch, Inc. dated March 22, 2000 (1).
     3.15  Certification of Designation, Preferences, Rights and Limitations of
           the Series C 8% Convertible Preferred Stock of HealthWatch, Inc.
           dated March 20, 2000 (1).
     3.16  Certification of Designation, Preferences, Rights and Limitations of
           the Series D 8% Convertible Preferred Stock of HealthWatch, Inc.
           dated March 20, 2000 (1).
      4.1  Specimen form of the Company's Common Stock certificate (2)
      4.8  Subscription and Purchase Agreement dated as of the 14th day of
           August 1992 between the Company and the Purchasers of the Company's
           10% convertible senior debentures due 1997 (including as an appendix
           thereto the form of the debenture certificate) (3)
     10.1  Business Collaboration Agreement dated as of October 10, 1997 between
           HealthWatch, Inc. and Halis, Inc. (1)
     10.6  Form of Warrant Certificate of HealthWatch, Inc. (1)
     10.8  Amended and Restated Agency Agreement between Commonwealth
           Associates, L.P. and HealthWatch, Inc. dated February 7, 2000 (1).
     10.9  HealthWatch, Inc. 2000 Stock Option Plan, adopted as of May 8, 2000,
           approved by HealthWatch stockholders July 14 2000 (1).
    10.10  Form of Stock Option Agreement (1).
    10.11  Amendment to the Business Collaboration Agreement dated September 20,
           2000 between Halis, Inc. and HealthWatch, Inc. (1)
    10.12  Finders Agreement between HealthWatch, Inc. and Commonwealth
           Associates, L.P., dated March 21, 2000 (1)
     21.1  Subsidiaries of HealthWatch, Inc. (1).

                                       16

<PAGE>

     (b)  REPORTS ON FORM 8-K. The following reports on Form 8-K were filed
          during the quarter ended December 31, 2001.

          None.
    -------------------------

     (1)  Incorporated herein by reference to the Company's Registration
          Statement on Form S-4, as amended, originally filed on October 24,
          2000 ( File No. 333-48546).
     (2)  Incorporated herein by reference to Registration Statement on Form
          S-18 (File No. 2-85688D).
     (3)  Incorporated herein by reference to Registration Statement on Form
          SB-2 (File No. 33-73462).




                                       17

<PAGE>

                                   SIGNATURES

     In accordance with the Exchange Act, the registrant caused this report to
be signed by the undersigned, thereunto duly authorized.

                                                   HEALTHWATCH, INC.

Date: February 14, 2002                            /s/ Paul W. Harrison
                                                   --------------------
                                                   Paul W. Harrison
                                                   Chairman, President and
                                                      Chief Executive Officer

Date: February 14, 2002                            /s/ Thomas C. Ridenour
                                                   ----------------------
                                                   Chief Financial Officer and
                                                    Principal Accounting Officer

                                       18

<PAGE>

                                  EXHIBIT INDEX

Number            Description

      2.1  Agreement and Plan of Merger by and among Halis, Inc., HealthWatch
           Merger Sub, Inc. and HealthWatch, Inc. dated as of June 29, 2000 (1).
      2.2  Amendment to the Agreement and Plan of Merger dated as of September
           29, 2000 (1).
      2.3  Letter of Intent between HealthWatch, Inc. and Halis, Inc. dated
           March 8, 2000 (1).
      2.4  Amendment to the Financing Option between HealthWatch, Inc. and
           Halis, Inc. dated July 28, 2000 (1).
      2.5  Second Amendment to the Agreement and Plan of Merger, dated as of
           January 31, 2001 (1).
      2.6  Third Amendment to the Agreement and Plan of Merger, dated as of
           February 16, 2001 (1).
      2.7  Fourth Amendment to the Agreement and Plan of Merger, dated as of
           March 28, 2001 (1).
      2.8  Fifth Amendment to the Agreement and Plan of Merger, dated as of
           April 26, 2001 (1).
      3.1  Articles of Incorporation of HealthWatch, Inc., dated June 10, 1983
           (1).
      3.2  Certificate of Amendment of Articles of Incorporation of HealthWatch,
           Inc., dated October 20, 1987(1)
      3.3  Articles of Amendment of Articles of Incorporation of HealthWatch,
           Inc., dated December 5, 1989 (1).
      3.4  Articles of Amendment of Articles of Incorporation of HealthWatch,
           Inc., dated December 8, 1999 (1).
      3.5  Bylaws of HealthWatch, Inc. (1).
     3.13  Certification of Designation, Preferences, Rights and Limitations of
           the 6% Series A Convertible Preferred Stock of HealthWatch, Inc.
           dated June 9, 1998 (1).
     3.14  Amended and Restated Certification of Designation, Preferences,
           Rights and Limitations of the Series P Preferred Stock of
           HealthWatch, Inc. dated March 22, 2000 (1).
     3.15  Certification of Designation, Preferences, Rights and Limitations of
           the Series C 8% Convertible Preferred Stock of HealthWatch, Inc.
           dated March 20, 2000 (1).
     3.16  Certification of Designation, Preferences, Rights and Limitations of
           the Series D 8% Convertible Preferred Stock of HealthWatch, Inc.
           dated March 20, 2000 (1). 4.1 Specimen form of the Company's Common
           Stock certificate (2) 4.8 Subscription and Purchase Agreement dated
           as of the 14th day of August 1992 between the Company and the
           Purchasers of the Company's 10% convertible senior debentures due
           1997 (including as an appendix thereto the form of the debenture
           certificate) (3)
     10.1  Business Collaboration Agreement dated as of October 10, 1997 between
           HealthWatch, Inc. and Halis, Inc. (1)
     10.6  Form of Warrant Certificate of HealthWatch, Inc. (1)
     10.8  Amended and Restated Agency Agreement between Commonwealth
           Associates, L.P. and HealthWatch, Inc. dated February 7, 2000 (1).
     10.9  HealthWatch, Inc. 2000 Stock Option Plan, adopted as of May 8, 2000,
           approved by HealthWatch stockholders July 14 2000 (1).
    10.10  Form of Stock Option Agreement (1).
    10.11  Amendment to the Business Collaboration Agreement dated September 20,
           2000 between Halis, Inc. and HealthWatch, Inc. (1)
    10.12  Finders Agreement between HealthWatch, Inc. and Commonwealth
           Associates, L.P., dated March 21, 2000 (1)

                                       19

<PAGE>

     21.1 Subsidiaries of HealthWatch, Inc. (1)



------------------------

     (1)  Incorporated herein by reference to the Company's Registration
          Statement on Form S-4, as amended, originally filed on October 24,
          2000 ( File No. 333-48546).
     (2)  Incorporated herein by reference to Registration Statement on Form
          S-18 (File No. 2-85688D).
     (3)  Incorporated herein by reference to Registration Statement on Form
          SB-2 (File No. 33-73462).


                                       20